|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00361023 |
|
Date of registration:
|
01/08/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
|
|
Scientific title:
|
Effects of Angiotensin Type 1 Receptor Blockade With Losartan on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes and Nephropathy |
|
Date of first enrolment:
|
January 2006 |
|
Target sample size:
|
25 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00361023 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Contacts
|
|
Name:
|
Hui M Jin, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Shanghai NO.3 people's Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
- 2h plasma glucose level of 7.5-13 mmol/L
- Body mass index (BMI) of 22 kg/m2
- Two occasions of a ratio of urinary albumin to urinary creatinine=300 or 24 hours
urinary protein concentration is >150mg.
- Informed consent
Exclusion Criteria:
- Type1 diabetes or nondiabetic renal disease
Age minimum:
17 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetic Nephropathy
|
|
Type 2 Diabetes
|
|
Intervention(s)
|
|
Drug: losartan
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|